Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pauline Tesson"'
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Supplementary Figure 3: NF2 deleterious mutations and sensitivity to lorlatinib (corresponding to main Figure 4).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::295ddc322c4e352d2e365e9861f1b33b
https://doi.org/10.1158/1078-0432.22474059
https://doi.org/10.1158/1078-0432.22474059
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Purpose:Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497a587b9ae25004327b21a79ff50bad
https://doi.org/10.1158/1078-0432.c.6528672
https://doi.org/10.1158/1078-0432.c.6528672
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Supplementary Figure 4: NF2 inhibition of mTORC1 and its canonical pathway.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a983bbc39dbae76176fe0634295730b
https://doi.org/10.1158/1078-0432.22474056.v1
https://doi.org/10.1158/1078-0432.22474056.v1
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Supplementary figures legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf2d32d7f78b8b3bf5bb97fa77f464e1
https://doi.org/10.1158/1078-0432.22474053
https://doi.org/10.1158/1078-0432.22474053
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Supplementary Figure 1: EMT mediated lorlatinib resistance (corresponding to main Figure 2).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2ba8d2529044d0ba489477fed9993f1
https://doi.org/10.1158/1078-0432.22474068
https://doi.org/10.1158/1078-0432.22474068
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Supplementary Figure 2: ALK secondary mutations (corresponding to main Figure 3).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab28b15c018bb59556e50ced7cd06212
https://doi.org/10.1158/1078-0432.22474065.v1
https://doi.org/10.1158/1078-0432.22474065.v1
Autor:
Jean-Yves Scoazec, Jean-Charles Soria, Gonzalo Recondo, Aurelie Abou Lovergne, Gilles Vassal, Tony Sourisseau, Pernelle Lavaud, Justine Galissant, Nathalie Auger, Antoine Hollebecque, Laura Mezquita, Alexander M.M. Eggermont, Maud Ngo-Camus, Karen Howarth, Christophe Massard, Rastilav Bahleda, David Planchard, Rosa L. Frias, Lambros Tselikas, Anas Gazzah, Fabrice Andre, Eric Angevin, Stefan Michiels, Floriane Braye, Luc Friboulet, Ken A. Olaussen, Ahsan Z. Rizvi, Linda Mahjoubi, Ludovic Bigot, Claudio Nicotra, Francesco Facchinetti, C. Naltet, Pauline Tesson, Ludovic Lacroix, D. O. Samofalova, Benjamin Besse, Eric Solary, Catherine Richon, Thierry de Baere, Jean Paul Thiery, Olivier Deas
Publikováno v:
Clin Cancer Res
Clinical Cancer Research
Clinical Cancer Research
Purpose:Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound